ADVA
1.4.2020 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that the European Advanced Networking Test Center (EANTC) has validated the interoperability of its unique carrier-grade network operating system (NOS) with routers and network management systems from a wide range of vendors. ADVA’s Ensemble Activator successfully demonstrated interoperability in a series of tests showing how disaggregated packet devices can significantly enhance the scale and functionality of networks. The software-based NOS, which turns bare-metal switches into powerful packet network devices, proved fully compatible with third-party switching and routing devices while supporting segment routing and MPLS Layer 3 services. What’s more, it showed ease of integration into third-party management systems through open interfaces for telemetry streaming and SDN control. Conducted at the EANTC’s facility in Berlin, the tests highlight the value of openness and show how Ensemble Activator can complement legacy packet networks with disaggregated packet devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200401005039/en/
“Putting our Ensemble Activator through EANTC’s rigorous tests emphasizes the commitment to openness and interoperability that underpins all ADVA innovation. But we’re also showing the industry how we can bring something special to Layer 3. Our years of experience with lower layer solutions give us a unique understanding of the operational aspects of networks,” said Eli Angel, VP, product line management, ADVA. “Our Ensemble Activator is proven to enable high-value disaggregated cell site gateway solutions, bringing the agility of software-based feature development to mobile networks. Now, we’re going even further and extending our unique MEF 3.0-certified solution with higher layer networking capabilities. These tests highlight how our Ensemble Activator supports segment routing and MPLS. What more, our disaggregated packet solution releases communication service providers from vendor lock-in and delivers total agility.”
Engineered specifically for white box switching, ADVA’s Ensemble Activator is the result of years of experience in deploying optical, Carrier Ethernet and IP/MPLS networks. The NOS is designed for zero-touch provisioning using the Open Networking Install Environment (ONIE) framework. Its success in the latest round of EANTC tests demonstrates how Ensemble Activator’s open management and control interfaces support easy integration into multi-vendor networks. ADVA’s strategy of extending its software capabilities from Layer 2 to higher layer functions offers the market a fresh approach to deploying flexible, feature-rich software-based MPLS routing and segment routing solutions in an open environment. ADVA’s long experience of building disaggregated telecommunication infrastructure will bring a host of benefits to operators and users of virtual private networks.
“Our evaluation confirms that Ensemble Activator successfully interworked with third-party routers and network management systems. In environments featuring technology from other major vendors, ADVA’s disaggregated software NOS was verified in tests focused on Layer 2 and Layer 3 VPNs, segment routing, and control and data plane capabilities,” commented Carsten Rossenhövel, managing director, EANTC. “This latest interoperability event was a major success with more than 100 attendees from 16 vendors, including many participating remotely. Its program reflected a shift across the industry to software-defined networking with many testing scenarios involving programmability and manageability. ADVA’s Ensemble Activator easily integrated and successfully interoperated in several of these tests, such as those focused on vendor-neutral Layer 3 segment routing and telemetry streaming.”
Further information on the interoperability testing is available on the EANTC website: https://adva.li/eantc-2020 .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About EANTC
EANTC (European Advanced Networking Test Center) is internationally recognized as one of the world's leading independent test centers for telecommunication technologies. Based in Berlin, Germany, the company offers vendor-neutral consultancy and realistic, reproducible high-quality testing services since 1991. Customers include leading network equipment manufacturers, tier-1 service providers, large enterprises and governments worldwide. EANTC's proof of concept, acceptance tests and network audits cover established and next-generation fixed and mobile network technologies. www.eantc.de
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005039/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom